Updated ownership structure after completion of the rights offering

SOLNA, Sweden - Aerocrine AB (Nasdaq Stockholm: AERO) updates information about its largest shareholders after a successful completion of the rights issue.  Novo A/S maintained their ownership position of 25.2 % and Invifed AB (part of Investor AB) increased their position to 24.8% according to Euroclear records as per February 20, 2015.

“A strong and supportive shareholder base is a prerequisite for Aerocrine. We are pleased to see that our two largest owners put trust in Aerocrine’s future success.  Novo A/S maintained their ownership position of 25.2%. Invifed AB, part of Investor AB,  increased their ownership to 24.8 percent”, comments Rolf Classon, Chairman of the Board.

Aerocrine will publish its report for the first quarter 2015 on May 12 at 08:00 am CET.

For more information about Aerocrine:

Scott Myers, Chief Executive Officer, Aerocrine AB, Phone: +1 970 368 0336

Marshall Woodworth, Chief Financial Officer, Aerocrine AB: +1 919 749 8748 or +46 709 695 219

or visit www.aerocrine.com

About Aerocrine

Aerocrine AB is a medical products company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in technology to monitor and manage airway inflammation, Aerocrine markets NIOX MINO® and NIOX VERO®.  Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the U.S., Germany, Switzerland and the U.K. Aerocrine shares were listed on the Stockholm Stock Exchange in 2007.

About Us

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Subscribe

Media

Media

Documents & Links